Avigen Inc. (AVGN)

HEALTH CARE: PHARMACEUTICALS
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

1301 HARBOR BAY PARKWAY ALAMEDA, CA 94502

Avigen Inc. seeks to develop and commercialize small molecule therapeutics and biologics to treat serious neurological and neuromuscular disorders. This biopharmaceutical company's lead product candidates, AV650 and AV411, primarily address neuromuscular spa® and spasticity and neuropathic pain.

View SEC Filings from AVGN instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AVGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVGN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HOROVITZ ZOLA P

  • Director
No longer subject to file 2009-12-18 0

PRENDERGAST JOHN K A

  • Director
No longer subject to file 2009-12-18 0

OHRSTROM JAN K

  • Director
No longer subject to file 2009-12-18 0

WALLACE RICHARD JOHN

  • Director
No longer subject to file 2009-12-18 0

DILLY STEPHEN GEORGE

  • Director
No longer subject to file 2009-12-18 0

SOUTHPAW ASSET MANAGEMENT LP

SOUTHPAW CREDIT OPPORTUNITY MASTER FUND, L.P.

SOUTHPAW HOLDINGS LLC

WYMAN KEVIN

GOLDEN HOWARD

  • 10% Owner
No longer subject to file 2009-12-18 0

CHAHINE KENNETH

  • Director
No longer subject to file 2009-12-18 0

JOHNSON KIRK WILLIAM VP RESEARCH AND DEVELOPMENT

  • Officer
No longer subject to file 2009-12-18 0

SAUTER ANDREW AUGUST CEO, PRESIDENT AND CFO

  • Officer
No longer subject to file 2009-12-18 0

BURLINGAME ASSET MANAGEMENT, LLC

  • 10% Owner
2,155,638 2009-12-14 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

LAMPERT MARK N

BVF INC/IL

  • 10% Owner
  • DIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNER
31,348,756 2009-11-18 0

BVF ACQUISITION LLC

  • SEE EXPLANATION OF RESPONSES
0 2009-01-23 0

LAMPERT MARK N

  • 10% Owner
8,819,600 2009-01-09 0

PERRY MATTHEW D

  • SEE EXPLANATION OF RESPONSES
0 2009-01-09 0

COPPEDGE ROBERT M

  • SEE EXPLANATION OF RESPONSES
0 2009-01-09 0

NODELMAN OLEG

  • SEE EXPLANATION OF RESPONSES
0 2009-01-09 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
8,310,015 2008-11-18 0

IWAKI YUICHI

  • Director
7,236 2008-05-05 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments